Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 17/20 | 0.55 |
| ▸ | MAPK3 | P27361 | 9/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153368 | 0.84 | MAPK1 (0.55) | MAPK1MAPK3MMP2MMP13ADAMTS5 | |
| SCHEMBL10235508 | 0.81 | MAPK1 (0.87) | MAPK1MAPK3CYP3A4 | |
| SCHEMBL1199745 | 0.75 | MMP2 (0.46) | MAPK1MMP2MMP13ADAMTS5ALDH1A1 | |
| SCHEMBL10235631 | 0.71 | MAPK1 (1.00) | MAPK1MAPK3CYP3A4 | |
| SCHEMBL4231255 | 0.70 | MAPK1 (0.52) | MAPK1MAPK3ALDH1A1MAPT | |
| SCHEMBL2466579 | 0.70 | MAPK1 (0.64) | MAPK1MAPK3ALDH1A1MAPTCYP3A4 | |
| SCHEMBL4220089 | 0.69 | MAPK1 (0.51) | MAPK1MAPK3ALDH1A1MAPT | |
| SCHEMBL4213861 | 0.69 | MAPK1 (0.51) | MAPK1MAPK3ALDH1A1MAPT | |
| SCHEMBL3155460 | 0.69 | MAPK1 (0.63) | MAPK1MAPK3ALDH1A1MAPT | |
| SCHEMBL2471086 | 0.69 | MAPK1 (0.52) | MAPK1MAPK3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2155722-B1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2155722-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2008153858-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | MAPK1 1/4885MAPK3 6/4885MMP2 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.